Federal Register / Vol. 80, No. 37 / Wednesday, February 25, 2015 / Notices 10129 

This information will help inform this 

strategic planning process and provide 

evidence to inform decisions on 

potential investments in grants for 

oncology nursing education in LMICs. 

Additionally, this information will be 

used in an online, interactive map that 

is being developed by CGH which will 

allow external organizations, such as 

cancer centers, to explore what projects 

are being done in which countries, 

which will facilitate collaborations and 

minimize duplication. The frequency of 

the data collection will be once per year 

although respondents may have more 

than one response if they have up to 

three projects. 

OMB approval is requested for 3 

years. There are no costs to respondents 

other than their time. The total 

estimated annualized burden hours are 

51. 

ESTIMATED ANNUALIZED BURDEN HOURS

Type of respondents 

Number of 

respondents/ 

year 

Number of 

responses per 

respondent 

Average burden per response 

(in hours) 

Total annual 

burden hours 

Directors of Nursing ......................................................................................... 68 3 15/60 51 

Dated: February 19, 2015. 

Karla Bailey, 

NCI Project Clearance Liaison, National 

Institutes of Health. 

[FR Doc. 2015–03788 Filed 2–24–15; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: The inventions listed below 

are owned by an agency of the U.S. 

Government and are available for 

licensing in the U.S. in accordance with 

35 U.S.C. 209 and 37 CFR part 404 to 

achieve expeditious commercialization 

of results of federally-funded research 

and development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing. 

FOR FURTHER INFORMATION CONTACT: 

Licensing information and copies of the 

U.S. patent applications listed below 

may be obtained by writing to the 

indicated licensing contact at the Office 

of Technology Transfer, National 

Institutes of Health, 6011 Executive 

Boulevard, Suite 325, Rockville, 

Maryland 20852–3804; telephone: 301– 

496–7057; fax: 301–402–0220. A signed 

Confidential Disclosure Agreement will 

be required to receive copies of the 

patent applications. 

SUPPLEMENTARY INFORMATION: 

Technology descriptions follow. 

HbF Induction Therapy for Sickle Cell 

Disease and Thalassemias 

Description of Technology: Sickle cell 

disease and thalassemia are hereditary 

disorders marked by the disruption in 

the pathways responsible for carrying 

oxygen to red blood cells. Symptoms 

associated with these disorders include 

anemia, jaundice, and severe pain. It has 

been shown that mutations during the 

development of fetal to adult 

hemoglobin can contribute to a delay in 

red blood cell maturity underlying 

sickle cell disease. As a result, there has 

been an increased focus on treatments 

that promote the induction of fetal 

hemoglobin (HbF) to improve clinical 

symptoms and ameliorate the severity of 

the diseases. Researchers at the National 

Institute of Diabetes and Digestive and 

Kidney Diseases have identified 

methods of increasing fetal hemoglobin 

by increasing the expression of Lin28 or 

decreased expression of let-7 microRNAs. The lead inventor and colleagues 

have developed novel lentiviral 

expression vectors containing 

hemoglobin regulators under the control 

of erythroid-specific promoters that can 

be used to increase Hbf expression 

without affecting the maturity of red 

blood cells. In addition, they have 

found, through the use of tough decoy 

inhibition of Let-7 micro-RNAs, a 

selection of Let-7 genes with greater 

involvement in HbF expression. This 

technology could lead to development 

of novel HbF induction therapies that 

reactivate and reduce the aberrant 

pathologies associated with human 

sickle-cell anemia and beta thalassemia. 

Potential Commercial Applications: 

• Ex vivo and in vivo therapeutics for 

treatment of sickle-cell anemia and beta 

thalassemias. 

• Potential use in combination with 

other transduction methods for unique 

therapeutic strategies. 

Competitive Advantages: 

• Reduced production of symptomassociated adult hemoglobin. 

• Lin28 overexpression at defined 

stage of hematopoietic cell 

development. 

• Therapeutic increases in patient 

HbF expression at lower viral titers than 

current direct transduction methods. 

• Improved safety and reduced 

toxicity as a result of erythroid-specific 

expression. 

Development Stage: 

• Early-stage 

• In vitro data available 

• In vivo data available (animal) 

Inventors: Jeffery L. Miller, Yuanwei 

T. Lee, Jaira F. de Vasconcellos, Colleen 

K. Byrnes (all of NIDDK) 

Intellectual Property: HHS Reference 

No. E–249–2014/0—US Provisional 

Application No. 62/046,247 filed 

September 5, 2014 

Related Technology: HHS Reference 

No. E–456–2013/2—PCT Application 

No. PCT/US2013/067811 filed October 

31, 2013, which published as WO 2014/ 

200557 on December 18, 2014 

Licensing Contact: Vince Contreras, 

Ph.D.; 301–435–4711; contrerasv@

mail.nih.gov 

Collaborative Research Opportunity: 

The National Institute of Diabetes and 

Digestive and Kidney Diseases is 

seeking statements of capability or 

interest from parties interested in 

collaborative research to further 

develop, evaluate or commercialize this 

technology. For collaboration 

opportunities, please contact Marguerite 

J. Miller at millermarg@niddk.nih.gov or 

301–496–9003. 

T Cell-Based Adoptive Transfer 

Immunotherapy for PolyomavirusAssociated Pathologies 

Description of Technology: Available 

for licensing are methods to generate T 

cells responsive to multiple 

polyomaviruses. The resulting T cell 

populations could be useful in treating 

immunosuppressed individuals with 

polyomavirus infections or 

polyomavirus-associated pathologies 

such as Merkel cell carcinoma (MCC), 

polyomavirus-associated nephropathy 

(PVAN), hemorrhagic cystitis, 


asabaliauskas on DSK5VPTVN1PROD with NOTICES
10130 Federal Register / Vol. 80, No. 37 / Wednesday, February 25, 2015 / Notices 

progressive multifocal 

leukoencephalopathy (PML), and 

trichodysplasia spinulosa (TS). The 

methods could also be used to restore 

polyomavirus-specific immunity in 

immunocompromised individuals. 

Potential Commercial Applications: 

Immunotherapy for immunosuppressed 

individuals with polyomavirusassociated pathologies. 

Competitive Advantages: Methods 

allow development of polyomavirus 

antigen-specific T cells. 

Development Stage: 

• Early-stage 

• In vitro data available 

Inventors: John A. Barrett (NHLBI), 

Dhanalakshmi Chinnasamy (NHLBI), 

Pawel J. Muranski (NHLBI), Christopher 

B. Buck (NCI) 

Intellectual Property: HHS Reference 

No. E–166–2014/0—US Application No. 

62/075,726 filed November 5, 2014 

Related Technologies: 

• HHS Reference No. E–168–2011 

• HHS Reference No. E–549–2013 

Licensing Contact: Patrick McCue, 

Ph.D.; 301–435–5560; mccuepat@

od.nih.gov 

Collaborative Research Opportunity: 

The National Heart, Lung, and Blood 

Institute is seeking statements of 

capability or interest from parties 

interested in collaborative research to 

further develop, evaluate or 

commercialize methods to generate T 

cells responsive to multiple 

polyomaviruses. For collaboration 

opportunities, please contact Dr. 

Vincent Kolesnitchenko at kolesniv@

nhlbi.nih.gov. 

89Zr-Oxine Complex for In Vivo PET 

Imaging of Labelled Cells and 

Associated Methods 

Description of Technology: This 

technology relates to a Zirconium-89 

(89Zr)-oxine complex for cell labeling, 

tracking of labeled cells by whole-body 

positron emission tomography/

computed tomography (PET/CT) 

imaging, and associated methods. A 

long half-life of 89Zr (78.4 hours), high 

sensitivity of PET and absence of 

background signal in the recipient 

enable tracking cells over a week using 

low levels of labeling radioactivity, 

without causing cellular toxicity. The 

89Zr-oxine complex is synthesized 

quickly by mixing components at room 

temperature and produces high yields. 

Cell labeling is achieved by a short, 

room temperature incubation. The 89Zroxine complex is capable of labeling a 

wide range of cell types of therapeutic 

or pathogenic relevance (natural, 

disease, engineered cells), independent 

of factors such as cell cycle or receptor 

expression. The label is retained during 

cell division. 89Zr-oxine labeled cells 

can also be easily cross labeled (for 

example, optically or magnetically) for 

multi-modality imaging and analysis. 

Labeled cell migration and kinetics can 

be analyzed and quantified in vivo over 

a week, improving research strategies 

and ability to develop and improve cell 

therapies and diagnostics. 

Potential Commercial Applications: 

Cell therapies and diagnostics. 

Competitive Advantages: Simple 

preparation, broadly applicable cell 

label, high resolution imaging and 

monitoring over period of a week, low 

toxicity, easily combined with labeling 

technologies and cell therapies. 

Development Stage: In vivo data 

available (animal). 

Inventors: Noriko Sato (NCI), Haitao 

Wu (NHLBI), Gary L. Griffiths (NCI), 

Peter L. Choyke (NCI) 

Publications: 

1. Sato N, et al. Generation and use of 

long-lasting cell labeling agent for 

positron emission tomography (PET) 

imaging. J Nucl Med. May 2014; 55 

(Supplement 1):273. 

2. Sato N, et al. 89Zr-oxine complex 

positron emission tomography (PET) 

cell imaging for monitoring cell-based 

therapies. Radiology, 2015, In press. 

Intellectual Property: HHS Reference 

No. E–080–2014/0—US Patent 

Application No. 61/973,706 filed April 

1, 2014 

Licensing Contact: Edward (Tedd) 

Fenn; 424–297–0336; Tedd.fenn@

nih.gov 

Collaborative Research Opportunity: 

The National Cancer Institute is seeking 

statements of capability or interest from 

parties interested in collaborative 

research to further develop, evaluate or 

commercialize cell labeling, cell 

tracking, cell trafficking, cell-based 

therapy, PET imaging. For collaboration 

opportunities, please contact John D. 

Hewes, Ph.D. at john.hewes@nih.gov or 

240–276–5515. 

Dated: February 18, 2015. 

Richard U. Rodriguez, 

Acting Director, Office of Technology 

Transfer, National Institutes of Health. 

[FR Doc. 2015–03779 Filed 2–24–15; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Member 

Conflict: Autoimmunity Transplantation 

Intolerance. 

Date: March 11, 2015. 

Time: 3:00 p.m. to 7:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892, 

(Telephone Conference Call). 

Contact Person: Betty Hayden, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4206, 

MSC 7812, Bethesda, MD 20892, 301–435– 

1223, haydenb@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Topics in 

Drug Discovery and Mechanisms of 

Antimicrobial Resistance. 

Date: March 13, 2015. 

Time: 8:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications 

Place: Residence Inn Bethesda, 7335 

Wisconsin Avenue, Bethesda, MD 20814. 

Contact Person: Guangyong Ji, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3211, 

MSC 7808, Bethesda, MD 20892, 301–435– 

1146, jig@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Skeletal 

Muscle related SBIR/STTR. 

Date: March 17, 2015. 

Time: 1:00 p.m. to 4:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892, 

(Telephone Conference Call). 

Contact Person: Richard Ingraham, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4116, 

MSC 7814, Bethesda, MD 20892, 301–496– 

8551, ingrahamrh@mail.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Program 

Project: Regulation of Cell Survival and 

Death Pathways by Fe-S Proteins. 

Date: March 19–20, 2015. 

Time: 11:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892, 

(Virtual Meeting). 


asabaliauskas on DSK5VPTVN1PROD with NOTICES